An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.

Trial Details

NCT ID
NCT07589569
Phase
PHASE2
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HRS-7058
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Informed consent was obtained from all participants before participating in the study.
  • Age from 18 to 75 years old (including both ends), regardless of gender;
  • Patients with locally advanced unresectable, recurrent unresectable or metastatic pancreatic cancer, and adenocarcinoma confirmed by cytology or hi…
  • Participants had received at least one previous systemic therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →